GeneDx (original) (raw)
From Wikipedia, the free encyclopedia
American biotechnology company
GeneDx
 |
|
|---|---|
| Company type | Public |
| Traded as | Nasdaq: WGS |
| Industry | Biotechnology, genome testing |
| Founded | 2000; 24 years ago (2000) |
| Founder | Sherri Bale, John Compton |
| Headquarters | Gaithersburg, Maryland |
| Key people | Katherine Stueland (CEO) Jason Ryan (Executive Chair of the Board) |
| Products | Exome/genome sequencing |
| Website | www.genedx.com |
GeneDx is a genetic testing company that was founded in 2000 by two scientists from the National Institutes of Health (NIH), Sherri Bale and John Compton.[1][2][3][4][5][6][7] They started the company to provide clinical diagnostic services for patients and families with rare and ultra-rare disorders, for which no such commercial testing was available at the time. The company started in the Technology Development Center, a biotech incubator supported by the state of Maryland and Montgomery County, MD. In 2006, BioReference Laboratories acquired GeneDx.[8] Since then, GeneDx has operated as a subsidiary of this parent company under the leadership of Bale (retired in 2016) and Compton (retired in 2013).[9] In October 2016, Benjamin D. Solomon was appointed as managing director.[10]
GeneDx works with the medical, scientific, and patient advocacy communities to continuously develop new genetic tests not currently available at other clinical laboratories. GeneDx currently offers tests for hundreds of rare diseases, as well as panels of genes and whole exome sequencing (20,000 gene) Mendelian disorders using massively-parallel DNA sequencing and deletion/duplication analysis of the associated gene(s). GeneDx also performs oligonucleotide-based microarray testing for the detection of chromosomal abnormalities (genomic losses or gains) in individuals with chromosomal anomalies. GeneDx provides testing for autism spectrum disorders, various forms of cardiomyopathy, inherited eye, skin, muscle, hearing, metabolic, neurologic, and mitochondrial disease.[_citation needed_]
GeneDx settled a patent dispute with Myriad Genetics in February 2015 after GeneDx launched a BRCA mutation breast cancer genetic screening test following the US Supreme Court decision in Association for Molecular Pathology v. Myriad Genetics, Inc. that concluded isolated gene sequences were patent ineligible.[11]
- ^ "GeneDX Founders Find Market for Diagnostic Tests". The Washington Post. Retrieved 2023-05-27.
- ^ "Maryland's Incubator Update" (PDF). Maryland State Archives. Retrieved 2023-05-27.
- ^ "About Us". GeneDx. Retrieved 2023-05-27.
- ^ "Rebranded GeneDx Bets Future on Whole-Exome, Whole-Genome Sequencing in Pediatric Rare Disease". GenomeWeb. Retrieved 2023-05-27.
- ^ "Montgomery College (Pinkney Innovation Complex for Science and Technology Foundation Officers)". Montgomery College. Retrieved 2023-05-27.
- ^ "Preliminary Offering Circular: GeneSystems, Inc". Securities and Exchange Commission Archives. Retrieved 2023-05-27.
- ^ "FORM 10-K/A: Bio-Reference Laboratories, Inc". Securities and Exchange Commission Archives. Retrieved 2023-05-27.
- ^ "N.J. biotech pays $17M in stock, cash for GeneDx". Bizjournals.com.
- ^ "Company Profile".
- ^ "OPKO Health Appoints Dr. Benjamin Solomon as Managing Director of GeneDx". www.businesswire.com. 2016-09-27. Retrieved 2019-07-18.
- ^ "GeneDx, Myriad Settle BRCA Patent Litigation". www.genomeweb.com. 16 February 2015.